Open-label, Randomized, Crossover Study to Investigate the Relative Bioavailability of Transdermally Administered Ethinylestradiol (EE) and Gestodene (GSD) After Repeated Applications of a Fertility Control Patch Containing 0.55 mg Ethinylestradiol and 2.1 mg Gestodene to 3 Different Application Sites (Buttocks, Arm Versus Abdomen) in Healthy Young Female Subjects.
Phase of Trial: Phase I
Latest Information Update: 08 Aug 2014
At a glance
- Drugs Ethinylestradiol/gestodene (Primary)
- Indications Pregnancy
- Focus Pharmacokinetics
- Sponsors Bayer
- 12 Jul 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 12 Jul 2010 Actual end date (May 2010) added as reported by ClinicalTrials.gov.
- 12 Jul 2010 Actual patient number is 43 according to ClinicalTrials.gov.